Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVB-620 in Primary Breast Cancer Surgery
NCT02391194Phase 1Completed
- Sponsor
- Avelas Biosciences, Inc.
- Start
- Apr 2015
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes, Peptides, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Pegloprastide in breast cancer, sponsored by Avelas Biosciences, Inc. Primary endpoint: Incidence of adverse events and abnormal laboratory values at 30 days. Started Apr 2015; status: completed.
02
Drugs
Pegloprastide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02391194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02391194.